FDA Sanctions Eli Lilly’s Easier-To-Use GLP-1 Weight Loss Pill Foundayo
Unlike Novo Nordisk's Wegovy pill, Lilly's orforglipron pill can be ingested at a user's leisure and is not required to be taken on an empty stomach. The company "designed this to fit into people鈥檚 lives as easily as possible," a Lilly official said. Plus, a group of teens has developed a wearable device to help people with dementia track everyday tasks.
The US Food and Drug Administration on Wednesday approved the second GLP-1 pill for weight loss, adding another option to a rapidly growing arsenal of obesity therapies. (Tirrell, 4/1)
The rapid rise of weight-loss injections is reshaping the quantity of food people eat 鈥 leaving farmers in some areas with a growing surplus of unsold potatoes. (McGreal, 4/1)
GLP-1 medications showed a range of potential benefits and safety concerns in an umbrella review of non-cardiometabolic outcomes, though the data quality for many remained limited. (Monaco, 3/31)
In other tech news 鈥
Meta is entering the health wearables market with AI glasses designed to keep tabs on what you eat. The Meta AI glasses are now available for people with prescription lenses and come with hands-free food tracking as part of a software update. Via a voice prompt or photo, wearers can log what they eat, with the glasses extracting nutrition details and logging them into the Meta AI app. (Bruce, 4/1)
Millions of people with dementia work hard to complete everyday tasks, from taking medication to locking the door. For families, keeping track of these small but essential routines can be exhausting, and missing a step can have serious consequences. Seeing a need through community and family, four juniors from Mount Hebron High School 鈥 Saanvi Kakarlapudi, 16; Ahana Roy, 16; Amitha Sabbani, 16; and Tanvi Anand, 17 鈥 developed MindLink, a wearable device designed to act as an automatic to-do list. (Yelenik, 4/1)
Scientists created virtual replicas of patients鈥 diseased hearts so precise that blocking a dangerous irregular heartbeat in these digital 鈥渢wins鈥 showed doctors how to better treat the real thing. One of the first clinical trials of these custom models suggests it might improve care for ventricular tachycardia, a notoriously difficult-to-treat arrhythmia that is a major cause of sudden cardiac arrest, blamed for about 300,000 U.S. deaths a year. (Neergaard, 4/1)
